Krystal Biotech, Inc. KRYS expects preliminary unaudited internet product revenues of $106-$107 million from lead drug Vyjuvek within the fourth quarter of 2025, bringing full-year 2025 income forecast to $388-$389 million.
The efficiency displays continued uptake in the USA and the profitable launch of Vyjuvek in Europe and Japan.
Krystal ended 2025 with roughly $955 million in money, money equivalents and investments, offering important monetary flexibility to fund scientific applications.
For 2026, Krystal expects mixed non-GAAP R&D and SG&A bills of $175-$195 million.
KRYS’s Different Pipeline Candidates
Krystal is accelerating improvement of a number of uncommon illness applications constructed on its redosable HSV-1 gene remedy platform, designed for high-turnover tissues comparable to pores and skin, lung and eye.
Key pipeline applications embody KB803 for ocular problems of DEB, KB801 for neurotrophic keratitis (NK), KB407 for cystic fibrosis (CF) and KB111 for Hailey-Hailey illness (HHD).
The corporate elevated enrollment in its registrational KB801 examine to 60 sufferers, signaling potential for expedited improvement. An in depth replace on the registrational examine design is predicted when it reviews its monetary leads to February 2026. High-line information from the examine is predicted earlier than the top of 2026.
Krystal’s long-term technique is to have a minimum of 4 marketed uncommon illness therapies by 2030, treating greater than 10,000 sufferers globally, whereas remaining worthwhile all through the enlargement part. In parallel, the corporate continues to spend money on earlier-stage applications addressing bigger indications, together with KB408 for alpha-1 antitrypsin deficiency and KB707 for non-small cell lung most cancers, which may present longer-term upside.
High-line information from each KB801 and KB803 registrational research are anticipated in 2026, representing necessary near-term catalysts.
KRYS additionally expects to report updates for each KB408 and KB707 earlier than the top of the yr.
Different targets for 2026 embody initiating and finishing enrollment in a registrational repeat dose examine evaluating KB407 for the remedy of CF. KRYS additionally plans to dose first affected person in registrational double-blind, intra-patient randomized, placebo-controlled examine evaluating KB111 in HHD sufferers.
Extra on KRYS’ Vyjuvek
In Might 2023, the FDA accepted Vyjuvek, the first-ever revocable gene remedy for treating sufferers aged six months or older with dystrophic epidermolysis bullosa (DEB).
In September 2025, the regulatory physique accepted a label replace for Vyjuvek that expanded the treatment-eligible inhabitants to incorporate DEB sufferers from delivery and offered sufferers with higher dosing flexibility, together with the choice for the remedy to be utilized by a healthcare skilled, caregiver, or immediately by the affected person themselves, both at dwelling or in a healthcare setting.
DEB is a uncommon and extreme monogenic illness that impacts the pores and skin and mucosal tissues. It’s attributable to a number of mutations in a gene referred to as COL7A1.
The remedy was additionally accepted in Japan and Europe in 2025, making it the primary and solely corrective remedy accepted for the remedy of DEB in every of these respective markets.
KRYS plans to increase Vyjuvek’s availability into further European markets in 2026 and broaden its specialty distributor community to succeed in greater than 40 nations.
KRYS’s Knowledge on Gene Remedy
Krystal Biotech just lately reported a optimistic interim scientific replace from the highest-dose cohort of its part I CORAL-1 examine evaluating KB407 in sufferers with CF.
The replace confirmed profitable lung supply and expression of full-length, wild-type CFTR protein following inhaled administration of KB407.
Importantly, molecular affirmation of CFTR expression was noticed throughout clinically related ciliated and secretory airway cells, no matter sufferers’ genetic background or eligibility for current CFTR modulator therapies.
The corporate submitted the proposed design for the CORAL-3 examine to the FDA in late December. CORAL-3 is meant to evaluate the protection and efficacy of repeat dosing with KB407, together with routine spirometry-based lung perform evaluations, and to assist a possible registration pathway. Exelixis expects to align with the FDA on the examine design within the first quarter of 2026 and to start enrolling sufferers within the second quarter of 2026, with further particulars to be disclosed nearer to check initiation.
Shares of KRYS have been up 5% on Jan. 9.
Krystal Biotech inventory has surged 73.9% in a yr in contrast with the business’s progress of 19.6%.
Picture Supply: Zacks Funding Analysis
KRYS had additionally reported optimistic interim security outcomes from the primary two dose escalation cohorts, known as Cohorts 1 and a couple of, within the fourth quarter of 2024.
The profitable improvement of different pipeline candidates will probably be a big enhance for KRYS.
Krystal’s Zacks Rank & Different Shares to Take into account
Krystal sports activities a Zacks Rank #1 (Sturdy Purchase) at current. A few different top-ranked shares within the pharma/biotech sector are CorMedix CRMD and Amicus Therapeutics FOLD, every carrying a Zacks Rank #1 at current. You’ll be able to see the whole record of at the moment’s Zacks #1 Rank shares right here.
Prior to now 60 days, estimates for CorMedix’s 2025 EPS have elevated from $2.49 to $2.88. CorMedix’s earnings beat estimates in every of the trailing 4 quarters, with a mean shock of 27.04%.
Prior to now 60 days, estimates for Amicus Therapeutics’ 2026 EPS have decreased to 67 cents from 70 cents. Shares of FOLD have gained 54.7% in a yr.
5 Shares Set to Double
Every was handpicked by a Zacks professional as the favourite inventory to realize +100% or extra within the months forward. They embody
Inventory #1: A Disruptive Power with Notable Progress and Resilience
Inventory #2: Bullish Indicators Signaling to Purchase the Dip
Inventory #3: One of many Most Compelling Investments within the Market
Inventory #4: Chief In a Pink-Sizzling Trade Poised for Progress
Inventory #5: Trendy Omni-Channel Platform Coiled to Spring
Many of the shares on this report are flying beneath Wall Road radar, which offers an excellent alternative to get in on the bottom ground. Whereas not all picks might be winners, earlier suggestions have soared +171%, +209% and +232%.
Obtain Atomic Alternative: Nuclear Power’s Comeback free at the moment.
Amicus Therapeutics, Inc. (FOLD) : Free Inventory Evaluation Report
CorMedix Inc (CRMD) : Free Inventory Evaluation Report
Krystal Biotech, Inc. (KRYS) : Free Inventory Evaluation Report
This text initially revealed on Zacks Funding Analysis (zacks.com).
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially replicate these of Nasdaq, Inc.
